NTRB earnings analysis
What we found in NTRB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q text does not include the financial statements or MD&A needed to assess revenue, margins, EPS, balance-sheet changes, cash flow, or segment trends; those metrics are therefore unavailable. Qualitatively, the filing is negative: disclosure controls remain ineffective, material weaknesses persist, and the company has 1 lead product in development but 0 products marketable in the United States. Litigation exposure includes claims exceeding $500,000 and a $100,000 unresolved settlement proposal, while geopolitical and capital-market risks could further impair liquidity.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Material control weaknesses remain
- The company disclosed that its disclosure controls and procedures were not effective under Exchange Act Rule 13a-15. Management identified material weaknesses involving segregation of duties, qualified accounting personnel, and reliance on third-party consultants, while also reporting additional monitoring controls and detailed reviews of revenue, receivables, and payables.
- Litigation exposure is significant
- The company is defending a lawsuit seeking more than $500,000 in damages plus punitive damages, while its counterclaims seek $1,000,000 for each of 2 claims. The case is in discovery, and a $100,000 settlement offer made in early 2024 remains unanswered.
- No U.S.-marketed product
- The filing states that the company has not completed development of its 1 lead product, an abuse-deterrent fentanyl transdermal system, and has 0 products it can market in the United States. It therefore cannot predict when or whether it will operate profitably.
- Geopolitical uncertainty adds pressure
- The company identified geopolitical and economic uncertainty, including the United States being involved in a war with Iran, as potential threats to tariffs, health-care and medical-product markets, margins, liquidity, and access to additional capital.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ineffective disclosure controls
- Disclosure controls were deemed ineffective as of the period end, with material weaknesses tied to the absence of segregation of duties, a lack of qualified accounting personnel, and reliance on third-party consultants. This raises the risk of reporting errors despite remediation efforts.
- Pending legal claims
- The company faces a lawsuit seeking more than $500,000 plus punitive damages, while legal fees are also sought by the plaintiff's counsel. The matter remains in discovery, and the company has not responded to a $100,000 settlement proposal made in early 2024.
- Regulatory and funding dependency
- The company has 1 lead product still in development and 0 products marketable in the United States. Delays in clinical trials or FDA review could extend losses and negative cash flow and prevent the company from achieving profitability.
What they said about what is next.
No quantitative revenue or EPS outlook is included in the supplied 10-Q text; outlook may be deferred to the earnings release or call.
The filing reads worse than the one before it.
What came before.
- 10-Q · June 11, 2026
- Nutriband Inc. reported a revenue decrease to $433,399 in Q4 2026 from $667,432 in Q4 2025, reflecting ongoing challenges with operational stability. Gross margins showed a slight deterioration after addressing higher…
- 10-K · May 18, 2026
- Nutriband Inc. (NTRB) reported ongoing financial challenges with continuing losses and negative profit margins throughout the fiscal year ended January 31, 2026. The company is also facing significant market pressures…
- 10-K · April 29, 2026
- Nutriband Inc. (NTRB) disclosed a challenging financial outlook in its 10-K, with the company experiencing substantial losses and negative profit margins in recent quarters. The filing highlights the impact of…
- 10-Q · December 11, 2025
- Nutriband reported Q3 revenue of $346,058, a 46.4% decline versus Q3 2024 revenue of $645,796 and a sharp sequential decline from the prior quarter. Gross margin fell to 19.8% while operating loss widened to $3,880,336…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NTRB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever